Natural killer cells contribute to enhanced respiratory disease after oil-in-water emulsion adjuvanted vaccination against respiratory syncytial virus and infection

References

• Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, Parrott RH. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 1969;89(4):422–34. doi:10.1093/oxfordjournals.aje.a120955.
   PubMed Web of Science ®Google Scholar
• Castilow EM, Olson MR, Varga SM. Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease. Immunol Res. 2007;39:225–39. doi:10.1007/s12026-007-0071-6.
   PubMed Web of Science ®Google Scholar
• Knudson CJ, Hartwig SM, Meyerholz DK, Varga SM. RSV vaccine-enhanced disease is orchestrated by the combined actions of distinct CD4 T cell subsets. PLoS Pathog. 2015;11:e1004757. doi:10.1371/journal.ppat.1004757.
   PubMed Web of Science ®Google Scholar
• Beyer WE, Palache AM, Osterhaus AD. Comparison of serology and reactogenicity between influenza subunit vaccines and whole virus or split vaccines: a review and meta-analysis of the literature. Clin Drug Investig. 1998;15:1–12. doi:10.2165/00044011-199815010-00001.
   PubMed Web of Science ®Google Scholar
• Soema PC, Kompier R, Amorij JP, Kersten GF. Current and next generation influenza vaccines: formulation and production strategies. Eur J Pharm Biopharm. 2015;94:251–63. doi:10.1016/j.ejpb.2015.05.023.
   PubMed Web of Science ®Google Scholar
• Lee Y, Ko EJ, Kim KH, Lee YT, Hwang HS, Jung YJ, Jeeva S, Kwon Y-M, Seong BL, Kang SM, et al. The efficacy of inactivated split respiratory syncytial virus as a vaccine candidate and the effects of novel combination adjuvants. Antiviral Res. 2019;168:100–08. doi:10.1016/j.antiviral.2019.05.011.
   PubMed Web of Science ®Google Scholar
• Del Giudice G, Rappuoli R, Didierlaurent AM. Correlates of adjuvanticity: a review on adjuvants in licensed vaccines. Semin Immunol. 2018;39:14–21. doi:10.1016/j.smim.2018.05.001.
   PubMed Web of Science ®Google Scholar
• Reed SG, Orr MT, Fox CB. Key roles of adjuvants in modern vaccines. Nat Med. 2013;19:1597–608. doi:10.1038/nm.3409.
   PubMed Web of Science ®Google Scholar
• Ko EJ, Lee YT, Kim KH, Jung YJ, Lee Y, Denning TL, Kang SM. Effects of MF59 adjuvant on induction of isotype-switched IgG antibodies and protection after immunization with T-dependent influenza virus vaccine in the absence of CD4+ T cells. J Virol. 2016;90:6976–88. doi:10.1128/JVI.00339-16.
   PubMed Web of Science ®Google Scholar
• Akache B, Deschatelets L, Harrison BA, Dudani R, Stark FC, Jia Y, Landi A, Law JLM, Logan M, Hockman D, et al. Effect of different adjuvants on the longevity and strength of humoral and cellular immune responses to the HCV envelope glycoproteins. Vaccines (Basel). 2019;7. doi:10.3390/vaccines7040204.
   PubMed Web of Science ®Google Scholar
• Jones DI, Pollara JJ, Johnson-Weaver BT, LaBranche CC, Montefiori DC, Pickup DJ, Permar SR, Abraham SN, Maddaloni M, Pascual DW, et al. Optimized mucosal modified vaccinia virus ankara prime/soluble gp120 boost HIV vaccination regimen induces antibody responses similar to those of an intramuscular regimen. J Virol. 2019;93:e00475–19.
   Web of Science ®Google Scholar
• Dai L, Zheng T, Xu K, Han Y, Xu L, Huang E, An Y, Cheng Y, Li S, Liu M, et al. A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS. Cell. 2020;182(3):722–33 e11. doi:10.1016/j.cell.2020.06.035.
   PubMed Web of Science ®Google Scholar
• Choubini E, Habibi M, Khorshidi A, Ghasemi A, Asadi Karam MR, Bouzari S. A novel multi-peptide subunit vaccine admixed with AddaVax adjuvant produces significant immunogenicity and protection against Proteus mirabilis urinary tract infection in mice model. Mol Immunol. 2018;96:88–97. doi:10.1016/j.molimm.2018.03.001.
   PubMed Web of Science ®Google Scholar
• Ko EJ, Kwon YM, Lee JS, Hwang HS, Yoo SE, Lee YN, Lee Y-T, Kim M-C, Cho MK, Lee YR, et al. Virus-like nanoparticle and DNA vaccination confers protection against respiratory syncytial virus by modulating innate and adaptive immune cells. Nanomedicine. 2015;11:99–108. doi:10.1016/j.nano.2014.07.013.
   PubMed Web of Science ®Google Scholar
• Kim KH, Lee YT, Hwang HS, Kwon YM, Jung YJ, Lee Y, Lee JS, Lee Y-N, Park S, Kang S-M, et al. Alum adjuvant enhances protection against respiratory syncytial virus but exacerbates pulmonary inflammation by modulating multiple innate and adaptive immune cells. PLoS ONE. 2015;10:e0139916. doi:10.1371/journal.pone.0139916.
   PubMed Web of Science ®Google Scholar
• Hwang HS, Kim KH, Lee Y, Lee YT, Ko EJ, Park S, Lee JS, Lee B-C, Kwon Y-M, Moore ML, et al. Virus-like particle vaccines containing F or F and G proteins confer protection against respiratory syncytial virus without pulmonary inflammation in cotton rats. Hum Vaccin Immunother. 2017;13:1031–39. doi:10.1080/21645515.2016.1272743.
   PubMed Web of Science ®Google Scholar
• Lee Y, Ko EJ, Kim KH, Lee YT, Hwang HS, Kwon YM, Graham BS, Kang SM. A unique combination adjuvant modulates immune responses preventing vaccine-enhanced pulmonary histopathology after a single dose vaccination with fusion protein and challenge with respiratory syncytial virus. Virology. 2019;534:1–13. doi:10.1016/j.virol.2019.05.010.
   PubMed Web of Science ®Google Scholar
• Isaacs A, Li Z, Cheung STM, Wijesundara DK, McMillan CLD, Modhiran N, Young PR, Ranasinghe C, Watterson D, Chappell KJ, et al. Adjuvant selection for influenza and RSV prefusion subunit vaccines. Vaccines (Basel). 2021;9. doi:10.3390/vaccines9020071.
   PubMed Web of Science ®Google Scholar
• Lee Y, Lee YT, Ko EJ, Kim KH, Hwang HS, Park S, Kwon Y-M, Kang SM. Soluble F proteins exacerbate pulmonary histopathology after vaccination upon respiratory syncytial virus challenge but not when presented on virus-like particles. Hum Vaccin Immunother. 2017;13:2594–605. doi:10.1080/21645515.2017.1362514.
   PubMed Web of Science ®Google Scholar
• Kon TC, Onu A, Berbecila L, Lupulescu E, Ghiorgisor A, Kersten GF, Cui Y-Q, Amorij J-P, Van Der Pol L. Influenza vaccine manufacturing: effect of inactivation, splitting and site of manufacturing. comparison of influenza vaccine production processes. PLoS ONE. 2016;11(3):e0150700. doi:10.1371/journal.pone.0150700.
   PubMed Web of Science ®Google Scholar
• Khater M, Macai J, Genyea C, Kaplan J. Natural killer cell regulation of age-related and type-specific variations in antibody responses to pneumococcal polysaccharides. J Exp Med. 1986;164:1505–15. doi:10.1084/jem.164.5.1505.
   PubMed Web of Science ®Google Scholar
• Nishikado H, Mukai K, Kawano Y, Minegishi Y, Karasuyama H. NK cell-depleting anti-asialo GM1 antibody exhibits a lethal off-target effect on basophils in vivo. J Immunol. 2011;186:5766–71. doi:10.4049/jimmunol.1100370.
   PubMed Web of Science ®Google Scholar
• Widjaja I, Wicht O, Luytjes W, Leenhouts K, Rottier PJM, Van Kuppeveld FJM, Haijema BJ, De Haan CAM. Characterization of epitope-specific anti-respiratory syncytial virus (Anti-RSV) antibody responses after natural infection and after vaccination with formalin-inactivated RSV. J Virol. 2016;90:5965–77. doi:10.1128/JVI.00235-16.
   PubMed Web of Science ®Google Scholar
• Chang J, Srikiatkhachorn A, Braciale TJ. Visualization and characterization of respiratory syncytial virus F-specific CD8(+) T cells during experimental virus infection. J Immunol. 2001;167:4254–60. doi:10.4049/jimmunol.167.8.4254.
   PubMed Web of Science ®Google Scholar
• Varga SM, Wissinger EL, Braciale TJ. The attachment (G) glycoprotein of respiratory syncytial virus contains a single immunodominant epitope that elicits both Th1 and Th2 CD4+ T cell responses. J Immunol. 2000;165:6487–95. doi:10.4049/jimmunol.165.11.6487.
   PubMed Web of Science ®Google Scholar
• Hwang HS, Kwon YM, Lee JS, Yoo SE, Lee YN, Ko EJ, Kim M-C, Cho M-K, Lee Y-T, Jung Y-J, et al. Co-immunization with virus-like particle and DNA vaccines induces protection against respiratory syncytial virus infection and bronchiolitis. Antiviral Res. 2014;110:115–23. doi:10.1016/j.antiviral.2014.07.016.
   PubMed Web of Science ®Google Scholar
• Hwang HS, Lee YT, Kim KH, Ko EJ, Lee Y, Kwon YM, Kang S-M. Virus-like particle vaccine primes immune responses preventing inactivated-virus vaccine-enhanced disease against respiratory syncytial virus. Virology. 2017;511:142–51. doi:10.1016/j.virol.2017.08.022.
   PubMed Web of Science ®Google Scholar
• Monnier J, Zabel BA. Anti-asialo GM1 NK cell depleting antibody does not alter the development of bleomycin induced pulmonary fibrosis. PLoS ONE. 2014;9:e99350. doi:10.1371/journal.pone.0099350.
   PubMed Web of Science ®Google Scholar
• Kasai M, Iwamori M, Nagai Y, Okumura K, Tada T. A glycolipid on the surface of mouse natural killer cells. Eur J Immunol. 1980;10:175–80. doi:10.1002/eji.1830100304.
   PubMed Web of Science ®Google Scholar
• Crouse J, Xu HC, Lang PA, Oxenius A. NK cells regulating T cell responses: mechanisms and outcome. Trends Immunol. 2015;36:49–58. doi:10.1016/j.it.2014.11.001.
   PubMed Web of Science ®Google Scholar
• Pallmer K, Oxenius A. Recognition and regulation of T cells by NK cells. Front Immunol. 2016;7:251. doi:10.3389/fimmu.2016.00251.
   PubMedGoogle Scholar
• Wong TM, Petrovsky N, Bissel SJ, Wiley CA, Ross TM. Delta inulin-derived adjuvants that elicit Th1 phenotype following vaccination reduces respiratory syncytial virus lung titers without a reduction in lung immunopathology. Hum Vaccin Immunother. 2016;12:2096–105. doi:10.1080/21645515.2016.1162931.
   PubMed Web of Science ®Google Scholar
• Lambert SL, Aslam S, Stillman E, MacPhail M, Nelson C, Ro B, Sweetwood R, Lei YM, Woo JC, Tang RS, et al. A novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models. PLoS ONE. 2015;10:e0119509. doi:10.1371/journal.pone.0119509.
   PubMed Web of Science ®Google Scholar
• Johnson TR, Hong S, Van Kaer L, Koezuka Y, Graham BS. NK T cells contribute to expansion of CD8(+) T cells and amplification of antiviral immune responses to respiratory syncytial virus. J Virol. 2002;76:4294–303. doi:10.1128/JVI.76.9.4294-4303.2002.
   PubMed Web of Science ®Google Scholar
• Schneider-Ohrum K, Cayatte C, Bennett AS, Rajani GM, McTamney P, Nacel K, Hostetler L, Cheng L, Ren K, O’Day T, et al. Immunization with low doses of recombinant postfusion or prefusion respiratory syncytial virus F primes for vaccine-enhanced disease in the cotton rat model independently of the presence of a Th1-biasing (GLA-SE) or Th2-biasing (Alum) adjuvant. J Virol. pp.91. 2017. doi:10.1128/JVI.02180-16.
   Web of Science ®Google Scholar
• Clark CM, Guerrero-Plata A. Respiratory syncytial virus vaccine approaches: a current overview. Curr Clin Microbiol Rep. 2017;4:202–07. doi:10.1007/s40588-017-0074-6.
   PubMed Web of Science ®Google Scholar
• Walsh EE, Peterson DR, Kalkanoglu AE, Lee FE, Falsey AR. Viral shedding and immune responses to respiratory syncytial virus infection in older adults. J Infect Dis. 2013;207:1424–32. doi:10.1093/infdis/jit038.
   PubMed Web of Science ®Google Scholar
• Cullen LM, Blanco JC, Morrison TG. Cotton rat immune responses to virus-like particles containing the pre-fusion form of respiratory syncytial virus fusion protein. J Transl Med. 2015;13:350. doi:10.1186/s12967-015-0705-8.
   PubMed Web of Science ®Google Scholar
• Topham NJ, Hewitt EW. Natural killer cell cytotoxicity: how do they pull the trigger? Immunology. 2009;128:7–15. doi:10.1111/j.1365-2567.2009.03123.x.
   PubMed Web of Science ®Google Scholar
• Ko E-J, Lee Y, Lee Y-T, Hwang HS, Park Y, Kim K-H, Kang S-M. Natural killer and CD8 T cells contribute to protection by formalin inactivated respiratory syncytial virus vaccination under a CD4-deficient condition. Immune Netw. 2020;20. doi:10.4110/in.2020.20.e51.
   Web of Science ®Google Scholar
• Tessmer MS, Fatima A, Paget C, Trottein F, Brossay L. NKT cell immune responses to viral infection. Expert Opin Ther Targets. 2009;13:153–62. doi:10.1517/14712590802653601.
   PubMed Web of Science ®Google Scholar
• Ferlazzo G, Morandi B. Cross-talks between natural killer cells and distinct subsets of dendritic cells. Front Immunol. 2014;5:159. doi:10.3389/fimmu.2014.00159.
   PubMed Web of Science ®Google Scholar
• Walzer T, Dalod M, Robbins SH, Zitvogel L, Vivier E. Natural-killer cells and dendritic cells: “l’union fait la force”. Blood. 2005;106:2252–58. doi:10.1182/blood-2005-03-1154.
   PubMed Web of Science ®Google Scholar
• Andoniou CE, van Dommelen SL, Voigt V, Andrews DM, Brizard G, Asselin-Paturel C, Delale T, Stacey KJ, Trinchieri G, Degli-Esposti MA, et al. Interaction between conventional dendritic cells and natural killer cells is integral to the activation of effective antiviral immunity. Nat Immunol. 2005;6:1011–19. doi:10.1038/ni1244.
   PubMed Web of Science ®Google Scholar
• Vitale M, Della Chiesa M, Carlomagno S, Pende D, Arico M, Moretta L, Moretta A. NK-dependent DC maturation is mediated by TNFalpha and IFNgamma released upon engagement of the NKp30 triggering receptor. Blood. 2005;106:566–71. doi:10.1182/blood-2004-10-4035.
   PubMed Web of Science ®Google Scholar